Roche Secures Dicerna RNAi Deal For Hepatitis B
Roche Pays $200m Up Front For DCR-HBVS Candidate
Roche has paid $200m up front to get its hands on Dicerna’s RNAi-based drug for chronic hepatitis B in a deal that could be worth around $1.5bn.
You may also be interested in...
At EASL 2020, four partnerships updated RNA-interference or antisense efforts to reduce hep B surface antigen, believed to lead to functional cure of the virus. One analyst sees J&J/Arrowhead as the early leader.
Financing for biopharma companies increased by 19% in Q4 to $15.8bn. M&A value quadrupled, compared with Q3, thanks to nine billion-dollar-plus transactions, led by the buy-out of Nestle Skin Health, now Galderma.Among the key alliances of Q4 were recurring themes of gene therapy and oncology, but also big investments in oligonucleotide technologies.
Novo Nordisk’s head of global drug discovery tells Scrip he hopes the strategic collaboration with Dicerna Pharmaceuticals will generate clinical candidates within three years.